

# Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2020-552 08 APR 2020

TO:

THE GENERAL PUBLIC

SUBJECT:

Public Health Warning Against the Purchase and Use of Cosmetic Products Containing Banned Ingredient/s as Reported in the ASEAN Post-Marketing Alert System (PMAS):

- 1. DNARS NIEN CREAM
- 2. GLOW GLOWING N GLOW
- 3. GLOW GLOWING T TREATMENT
- 4. DOLLY GLOW MIRACLE TREATMENT CREAM

The Food and Drug Administration (FDA) warns the public from purchasing and using the following adulterated cosmetic products, which tested positive for the presence of **HYDROQUINONE** and **TRETINOIN**, as reported in the ASEAN Post-Marketing Alert System (PMAS). These ingredients are not allowed to be part of a cosmetic product as per ASEAN Cosmetic Directive (ACD). The table below indicates the particulars of the adulterated cosmetic products:

# Product Details 1. Dnars Nien Cream Manufactured by/Local Company Responsible for Placing the Product in the Market: Top On Cosmetics Country of Manufacture: Malaysia Lot/Batch Number: NL00718 Manufacturing Date: Not Indicated Expiration Date: Not Indicated Not Indicated NIENCREM NIENCREM

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900
Fax +63 2 807 0751
Website: www.fda.gov.ph
Email: info@fda.gov.ph



### 2. Glow Glowing N Glow

Manufactured by/Local Company Responsible for Placing the Product in the Market: **Top On Cosmetics** Country of Manufacture: **Malaysia** 

Lot/Batch Number: **Not Indicated** Manufacturing Date: **Not Indicated** Expiration Date: **Not Indicated** 





### 3. Glow Glowing T Treatment

Manufactured by/Local Company Responsible for Placing the Product in the Market: **Top On Cosmetics** Country of Manufacture: **Malaysia** 

Lot/Batch Number: **Not Indicated**Manufacturing Date: **Not Indicated**Expiration Date: **Not Indicated** 



## 4. Dolly Glow Miracle Treatment Cream

Manufactured by/Local Company Responsible for Placing the Product in the Market: **Skintech** Country of Manufacture: **Thailand** 

Lot/Batch Number: **Not Indicated**Manufacturing Date: **Not Indicated**Expiration Date: **Not Indicated** 



The aforementioned products have been tested by the National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia as part of their post-marketing surveillance activities and results of the laboratory analyses show that these products are not compliant with the technical standards set forth by the ACD.

Hydroquinone and Tretinoin are not allowed to be part of cosmetic products as these are classified as drug products in the Philippines because of their multiple serious adverse effects, such as sensitivity to light, skin redness and permanent skin discoloration, when used indiscriminately. Additionally, tretinoin may also cause harm to developing fetus. Women planning to get pregnant or are already expecting are strongly advised to avoid using products containing tretinoin.

In light of the foregoing, the public is advised not to purchase the aforementioned adulterated products. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (<a href="www.fda.gov.ph">www.fda.gov.ph</a>) has a Search feature which may be used by typing in the name of the product before purchasing.

All concerned establishments are warned not to distribute adulterated cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.

Kindly contact the FDA Center for Cosmetics Regulation and Research through e-mail at ccrr@fda.gov.ph, or call (02) 8857-1900 loc. 8113 or 8107.

To report any sale or distribution of the afore-mentioned cosmetic product, the online reporting facility, **eReport** can be accessed at **www.fda.gov.ph/ereport**.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN: 20200331152425